Comparative Pharmacology
Head-to-head clinical analysis: DORIBAX versus ERTAPENEM SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORIBAX versus ERTAPENEM SODIUM.
DORIBAX vs ERTAPENEM SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doripenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against Gram-positive, Gram-negative, and anaerobic bacteria.
Ertapenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death. It is a carbapenem antibiotic with broad-spectrum activity against Gram-positive and Gram-negative aerobes and anaerobes.
1 g IV every 8 hours over 1 hour for complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis), and hospital-acquired pneumonia (including ventilator-associated pneumonia).
1 g IV or IM once daily.
None Documented
None Documented
Terminal elimination half-life approximately 1 hour in healthy adults; prolonged to ~4 hours in renal impairment (CrCl <30 mL/min).
Terminal half-life: ~4 hours (range 3.5-5.3) in young adults; prolonged in renal impairment (e.g., ~7.5 hours in moderate impairment, ~13 hours in end-stage renal disease)
Renal: approximately 70-75% unchanged in urine; biliary/fecal: minimal (less than 20% total, primarily as metabolite).
Renal: ~80% unchanged in urine; fecal: ~10% as metabolites; biliary: minimal (<1%)
Category C
Category A/B
Carbapenem Antibiotic
Carbapenem Antibiotic